Related Experiment Videos
[Suppression of non-specific bronchial hyperreactivity by DSCG (Disodium cromoglycate) and ipratropium bromide
Insights
Disodium cromoglycate (DSCG) effectively reduced airway constriction in children with bronchial hyperreactivity. This suggests DSCG may be beneficial for managing certain types of asthma by acting on irritative receptors.
Area of Science:
- Pulmonology
- Pharmacology
- Pediatrics
Background:
- Non-specific bronchial hyperreactivity is a condition affecting children.
- Acetylcholine challenges are used to induce and assess bronchial hyperreactivity.
- Disodium cromoglycate (DSCG) is known to inhibit mast cell degranulation.
Purpose of the Study:
- To investigate the protective activity of DSCG against acetylcholine-induced bronchial hyperreactivity in children.
- To compare the efficacy of DSCG with ipratropium bromide, an anticholinergic agent.
Main Methods:
- A study involving 18 children with established non-specific bronchial hyperreactivity.
- Bronchial challenge with acetylcholine to induce hyperreactivity.
- Administration of DSCG and ipratropium bromide for comparative analysis of protective effects.
Main Results:
- DSCG demonstrated a statistically significant inhibitory effect on the decrease in specific airway conductance.
- Ipratropium bromide, as expected, provided an overall protective effect.
- The findings suggest DSCG may have a direct action on cholinergic irritative receptors, beyond mast cell inhibition.
Conclusions:
- DSCG exhibits protective activity in children with bronchial hyperreactivity.
- The mechanism may involve direct action on cholinergic receptors, suggesting potential therapeutic use.
- DSCG could be considered for immunologically ill-defined forms of bronchial asthma.
Abstract:
The protective activity of DSCG was investigated in 18 children with established non-specific bronchial hyperreactivity induced by bronchial challenge with acetylcholine. Ipratropium bromide, the anticholinergic agent, was used for comparison. DSCG showed a statistically significant inhibitory action on the decrease in specific airway conductance. Besides the well-established inhibition of mast cell degranulation a direct action on cholinergic irritative receptors seems likely. Application of DSCG in immunologically ill-defined forms of bronchial asthma may be considered. As expected, the direct acetylcholine antagonist, ipratropium bromide, showed an overall protective effect.